GHK-Cu Dosage: What Human and Animal Studies Show
There is no tested GHK-Cu injection dosage for people. See the strengths used in human skin studies, animal injection doses, GLOW and KLOW vial amounts and FDA status.
Separating human skin studies, animal injection doses and online protocols.
There is no established injectable GHK-Cu dosage for people. The published controlled human studies identified in our review evaluated topical copper-peptide products, not injections. A ClinicalTrials.gov search conducted on November 8, 2026 identified four GHK-Cu-related study records, none evaluating an injectable dose. Online injection schedules are not supported by the human dose-finding evidence identified in this review.
Key takeaways
- No tested injectable dose: A ClinicalTrials.gov search on November 8, 2026 returned four GHK-Cu-related studies, all topical, patch or device studies. None of the four identified records evaluates an injected GHK-Cu dose.
- Human data are topical: Published human trials tested a 0.4% copper tripeptide wound cream and copper peptide skin care after laser resurfacing. A trial of a 0.1% topical gel was listed as recruiting on November 8, 2026.
- Animal doses do not convert: Rodent studies used different injected concentrations or body-weight-based doses, with different administration routes and experimental purposes. None establishes a human injection dose.
- Not FDA approved: Injectable GHK-Cu is not an FDA-approved drug, and it is not among the six peptides in HHS's October 2026 compounding enforcement-discretion policy.
- Vial math is not a dose: Knowing that a GLOW or KLOW vial holds 50 mg of GHK-Cu tells you what the label claims, not what amount is safe.
GHK-Cu dosage evidence at a glance
| Evidence category | Reported amount or strength | What it establishes |
|---|---|---|
| Human wound cream | 0.4% | Topical concentration tested; no superiority to placebo |
| Human post-laser skin care | Concentration not specified in the cited abstract | Topical outcomes; no objectively demonstrated superiority |
| Human phase 2 gel | 0.1% | Ongoing topical investigation, not established efficacy |
| Rat joint study | 0.3 or 3 mg/mL | Experimental solution concentration |
| Mouse lung study | 0.2, 2 or 20 µg/g | Experimental intraperitoneal dosing |
| Aged-mouse preprint | 15 mg/kg | Preliminary, non-peer-reviewed animal evidence |
| Human injection | No established dose | No validated human injection regimen identified |
The rat and mouse figures are experimental data, not human dosing instructions.
What is GHK-Cu?
GHK-Cu is a copper complex of GHK, a three-amino-acid peptide (glycine-histidine-lysine) that occurs naturally in human plasma, saliva and urine. Researchers report that GHK levels decline with age, and laboratory studies describe effects on collagen production, wound repair and inflammation signaling (Pickart et al., BioMed Research International, 2015). A 2023 study measured plasma GHK, the peptide component of GHK-Cu, in nine people with chronic obstructive pulmonary disease (COPD) and eleven healthy controls. The mean concentrations were approximately 70 ng/mL and 133 ng/mL, respectively (Deng et al., Journal of Cachexia, Sarcopenia and Muscle, 2023). Those natural levels describe what the body makes, not a dose to supplement.
Is there a recommended GHK-Cu injection dose?
No. A recommended dose normally comes from human studies that measure absorption, how long a drug lasts and which amounts cause side effects. We found no published human pharmacokinetic or dose-finding study of injected GHK-Cu. A 2026 review of approved and unapproved peptides used in sports medicine, which includes GHK-Cu, concluded that rigorous human safety data for the unapproved compounds are scarce and that there is potential for serious harm (Mendias and Awan, Sports Medicine, 2026).
Any specific milligram or microgram figure presented as "the" GHK-Cu injection dose is therefore an unverified convention, not a tested amount. A protocol repeated across many websites is still a protocol no one has tested in a trial.
What GHK-Cu strengths were used in human studies?
The human evidence comes from products applied to the skin:
- Venous leg ulcers, 0.4% cream: In a randomized, evaluator-blinded trial of 86 patients, a tripeptide copper complex 0.4% cream did not reduce ulcer size more than placebo; silver sulfadiazine cream did (Bishop et al., Journal of Vascular Surgery, 1992).
- Skin care after CO2 laser resurfacing: In a 13-patient randomized study, GHK-Cu skin care products did not objectively improve redness, wrinkles or skin quality compared with a regimen without GHK-Cu, although patients using GHK-Cu reported higher satisfaction (Miller et al., Archives of Facial Plastic Surgery, 2006).
- Recruiting now, 0.1% gel: A phase 2 trial is testing a 0.1% GHK-Cu gel applied once daily for 14 days to small skin wounds in healthy adults, compared with a vehicle gel (ClinicalTrials.gov NCT07437586). The trial was listed as recruiting when checked on November 8, 2026; published efficacy and safety results were not identified in this review.
Topical percentages describe a product's concentration, not an amount absorbed into the body, and they cannot be converted into an injection dose.
What GHK-Cu doses were used in animal studies?
Injected GHK-Cu has been investigated in rodents. Some studies report the concentration of the injected solution, while others report the amount administered per unit of body weight. These measurements are not interchangeable and do not establish a human dosing protocol.
- Rat knee ligament surgery: Rats received injections into the knee joint of 0.3 or 3 mg/mL GHK-Cu once a week for four weeks after ligament reconstruction. Knee laxity improved at six weeks but the difference was gone at 12 weeks (Fu et al., Journal of Orthopaedic Research, 2015).
- Mouse lung injury: Mice exposed to cigarette smoke received injections into the abdominal cavity of 0.2, 2 or 20 micrograms per gram of body weight on alternate days (Zhang et al., Frontiers in Molecular Biosciences, 2022).
- Aged mice: A 2026 preprint, not yet peer reviewed, gave 20- to 21-month-old mice 15 mg/kg GHK-Cu by intraperitoneal injection (into the abdominal cavity) for five days or by nasal spray for eight weeks (Mazzola et al., Research Square preprint, 2026).
These were preclinical experiments. Neither the rat nor the mouse studies establish a safe, effective or recommended dose for people, and the wide spread between them shows how much the amount depends on the model and route.
How much GHK-Cu is in GLOW and KLOW vials?
A typical 70 mg GLOW blend vial is labeled with 50 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500. A typical 80 mg KLOW blend vial is labeled with 50 mg of GHK-Cu, 10 mg of BPC-157, 10 mg of TB-500 and 10 mg of KPV. These are commonly advertised blend compositions, not independently verified contents or clinically established doses. Our glow peptide dosage chart and KLOW peptide dosage guide explain the labeled component quantities in more detail.
A vial labeled 50 mg contains a claimed total quantity of peptide. The label alone does not verify the substance's identity, purity, potency or suitability for human use, and concentration math describes what the vial contains, not what amount is safe.
How long does reconstituted GHK-Cu last?
The sources we reviewed do not establish a validated shelf life for GHK-Cu once it is mixed with water. Storage claims on research-peptide labels are not backed by the stability testing an approved drug label requires. General guidance on mixed peptides is covered in our guide to how long reconstituted peptides last.
Is injectable GHK-Cu FDA approved?
No. Injectable GHK-Cu is not an FDA-approved drug. It is also not among the six peptides (BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500) named in HHS's October 2026 interim enforcement-discretion policy for prescription compounding (HHS peptide enforcement-discretion policy). Our GHK-Cu FDA approval status guide covers the 2026 compounding history in detail.
What are the risks of injecting GHK-Cu?
They are not well characterized. Without human injection studies, there are no measured rates of side effects, no established safe amount and no data on long-term use. A product labeled for research use has not, by that label alone, demonstrated the identity, purity, potency, sterility or endotoxin controls needed to establish suitability for human injection. Contamination and product misidentification are additional concerns, separate from the unknown effects of GHK-Cu itself. Injection-site reactions such as redness, swelling or pain are covered in our guide to where GHK-Cu is injected.
Seek emergency care right away for signs of a severe allergic reaction (anaphylaxis), such as trouble breathing, swelling of the face, lips or throat, widespread hives, or fainting (MedlinePlus: anaphylaxis). Problems with a product can be reported to FDA MedWatch.
Frequently asked questions
What is the dosage for GHK-Cu peptide?
There is no established dosage for injected GHK-Cu in people. Human studies used topical products, such as a 0.4% cream, and the registered studies identified in our search did not evaluate injection dosing.
How much GHK-Cu should be injected per day?
No human study has determined a daily injected amount. Per-day figures on vendor and protocol sites are unverified conventions, not tested doses.
Is topical GHK-Cu dosage the same as injectable dosage?
No. A topical product is described by its concentration, such as 0.1% or 0.4%, and how much reaches the body is not known. That figure cannot be converted into an injection amount.
How much GHK-Cu is in KLOW?
A typical 80 mg KLOW vial is labeled with 50 mg of GHK-Cu, the same amount as a typical 70 mg GLOW vial.
Is GHK-Cu safe to inject?
Its safety by injection has not been established in human studies. A 2026 sports medicine review noted that human safety data for unapproved peptides such as GHK-Cu are scarce.
Sources
- Bishop JB et al. Venous stasis ulcer trial of tripeptide copper complex 0.4% cream. J Vasc Surg. 1992.
- Miller TR et al. Topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006.
- ClinicalTrials.gov NCT07437586. Topical GHK-Cu Gel for Acute Skin Wound Healing.
- Fu SC et al. GHK-Cu in a rat model of ACL reconstruction. J Orthop Res. 2015.
- Zhang Q et al. GHK-Cu and cigarette smoke-induced emphysema in mice. Front Mol Biosci. 2022.
- Mazzola J et al. GHK-Cu in middle-aged mice, intraperitoneal or intranasal. Res Sq preprint. 2026.
- Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015.
- Deng M et al. Plasma GHK in COPD and skeletal muscle dysfunction. J Cachexia Sarcopenia Muscle. 2023.
- Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies. Sports Med. 2026.
- HHS. 503A peptide enforcement-discretion policy. October 2026.
You Might Also Like

Where to Inject GHK-Cu: Best Injection Sites & How-To
Where to inject GHK-Cu? Review common subcutaneous sites, rotation rules, and why injectable GHK-Cu is not FDA-approved for human use.

GHK-Cu FDA Approval Status 2026: Injectable Rules
Is GHK-Cu FDA approved? No. Full 2026 regulatory status, Category 2 reclassification updates, compounding regulations, and published research.

Glow Peptide Dosage Chart | 70mg Blend
Glow peptide dosage chart for a 70mg blend: BAC-water reconstitution, U-100 syringe math, per-component amounts, and research conventions.

